newsfilter
← Latest News
GlobeNewswire·

argenx Announces Positive Topline Results from Phase 2 Study of FB102 in Celiac Disease

Study met primary endpoint of change from baseline in the ratio of Vh:Cd (p=0.0176)First Phase 2 evidence that blocking CD122 can prevent gluten-induced intestinal damage in people living with celiac diseaseargenx